Company intelligence / Profile preview

Martin Pharmaceuticals

New York, New York, United Statesmartinpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Recent findings from the DREAM study (Phase 2a open-label trial) evaluated the safety and efficacy of docarpamine in patients with refractory ascites. The trial enrolled 16 patients with refractory ascites requiring regular large-volume paracentesis, who received either a low dose (750 mg TID) or a high dose (1500 mg TID) of docarpamine for up to 90 days. The company has announced positive results from this study.

Therapeutic areas: Gastroenterology
Modalities: Small molecules (docarpamine/CIQUAAX®)
Industry: Biotech

Drug pipeline

1 asset

docarpamine

Unknown

Partnerships

Mitsubishi Tanabe Pharma Corporation (MTPC)

Beyond the preview

Go deeper on Martin Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Martin Pharmaceuticals.